The role of molecular diagnostics in cancer diagnosis and treatment

Onkologie

Volumn 35, Issue SUPPL. 1, 2012, Pages 8-12

  Ozretić, Luka ^a   Heukamp, Lukas C ^a   Odenthal, Margarete ^a   Buettner, Reinhard ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

EGFR; Lung cancer; Molecular diagnostics; Next generation sequencing

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GEFITINIB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER MORTALITY; CANCER THERAPY; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; NEOPLASM;

HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS;

EID: 84856501028     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/0003348235     Document Type: Article

References (49)

1. Jemal A, Center MM, DeSantis C, Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-907.
2. Burgess AW: EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 2008;26:263-74.
3. Roskoski R Jr: The ErbB/HER receptor proteintyrosine kinases and cancer. Biochem Biophys Res Commun 2004;319:1-11. (Pubitemid 38670153)
4. Akca H, Tani M, Hishida T, et al.: Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. Lung Cancer 2006;54:25-33.
5. Yano S, Kondo K, Yamaguchi M, et al.: Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 2003;23:3639-50. (Pubitemid 37474306)
6. Yarden Y, Schlessinger J: Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 1987;26:1443-51. (Pubitemid 17045875)
7. Sobol RE, Astarita RW, Hofeditz C, et al.: Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst 1987;79:403-7. (Pubitemid 17126586)
8. Ciardiello F, Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7:2958-70. (Pubitemid 32963812)
9. Stoscheck CM, King LE Jr: Role of epidermal growth factor in carcinogenesis. Cancer Res 1986; 46:1030-7. (Pubitemid 16048225)
10. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50. (Pubitemid 29255919)
11. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
12. Porebska I, Harlozinska A, Bojarowski T: Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000;21:105-15. (Pubitemid 30114656)
13. Chen Z, Ke LD, Yuan XH, Adler-Storthz K: Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells. Anticancer Res 2000;20:899-902. (Pubitemid 30240653)
14. Akimoto T, Hunter NR, Buchmiller L, et al.: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5:2884-90. (Pubitemid 29493967)
15. Normanno N, Bianco C, De Luca A, et al.: Targetbased agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr relat cancer 2003;10:1-21. (Pubitemid 36457237)
16. Harari PM: Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11:689-708. (Pubitemid 40065545)
17. Kollmannsberger C, Schittenhelm M, Honecker F, et al.: A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2006;17:1007-13. (Pubitemid 43778995)
18. Anderson NG, Ahmad T: ErbB receptor tyrosine kinase inhibitors as therapeutic agents. Front Biosci 2002;7:d1926-40.
19. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99. (Pubitemid 46606324)
20. Galizia G, Lieto E, De Vita F, et al.: Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007;26: 3654-60. (Pubitemid 46842715)
21. Saltz L, Rubin M, Hochster H, et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001;20:abstr 7.
22. Moroni M, Veronese S, Benvenuti S, et al.: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86. (Pubitemid 40590264)
23. Perez-Soler R, Chachoua A, Hammond LA, et al.: Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 2004;22:3238-47. (Pubitemid 41103678)
24. Pao W, Miller V, Zakowski M, et al.: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11. (Pubitemid 39209661)
25. Yang CH, Yu CJ, Shih JY, et al.: Specific EGFR mutations predict treatment outcome of stage IIIB/ IV patients with chemotherapy-naive non-smallcell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008;26:2745-53.
26. Rosell R, Moran T, Queralt C, et al.: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
27. Krasinskas AM: EGFR signaling in colorectal carcinoma. Patholog Res Int 2011;2011:932932.
28. Marchetti A, Milella M, Felicioni L, et al.: Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 2009;11:1084-92.
29. Ahrendt SA, Decker PA, Alawi EA, et al.: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001;92:1525-30. (Pubitemid 32947838)
30. Yousem SA, Nikiforova M, Nikiforov Y: The histopathology of BRAF-V600E-mutated lung adenocarcinoma. Am J Surg Pathol 2008;32:1317-21.
31. Yamamoto H, Shigematsu H, Nomura M, et al.: PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008;68:6913-21.
32. Carcereny E, Molina MA, Sanchez JJ, et al.: Mutations of the catalytic subunit a of PI3K (PIK3CA) in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations. J Clin Oncol 2011;29(suppl):abstr 7588.
33. Gandhi J, Zhang J, Xie Y, et al.: Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS ONE 2009;4:e4576.
34. Soda M, Choi YL, Enomoto M, Takada S, et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. (Pubitemid 47206930)
35. Shaw AT, Yeap BY, Mino-Kenudson M, et al.: Clinical features and outcome of patients with nonsmall cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53.
36. Inamura K, Takeuchi K, Togashi Y, et al.: EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009;22:508-15.
37. Pfizer Phase 2, open-label single arm study of the efficacy and safety of PF-02341066 in patients with non-small cell lung cancer harboring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene; in ClinicalTrials. gov. Bethesda (MD), National Library of Medicine (US), 2000 (cited 2011 Sept 09); available from //clinicaltrials.gov/ct2/show/ NCT00932451, identifier NCT00932451.
38. Kobayashi S, Boggon TJ, Dayaram T, et al.: EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92. (Pubitemid 40271173)
39. Sharma SV, Bell DW, Settleman J, Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
40. Yun CH, Boggon TJ, Li Y, et al.: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007; 11:217-27. (Pubitemid 46349842)
41. Maheswaran S, Sequist LV, Nagrath S, et al.: Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-77.
42. Sos ML, Koker M, Weir BA, et al.: PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009;69:3256-61.
43. Engelman JA, Zejnullahu K, Mitsudomi T, et al.: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43. (Pubitemid 46799492)
44. Weiss J, Sos ML, Seidel D, et al.: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2: 62ra93.
45. Dutt A, Ramos AH, Hammerman PS, et al.: Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011; 6:e20351.
46. Novartis Pharmaceuticals A phase I, open-label, multi-center, dose escalation study of Oral BGJ398, a Pan FGF-R kinase inhibitor, in adult patients with advanced solid malignancies; in ClinicalTrials.gov. Bethesda (MD), National Library of Medicine (US), 2000 (cited 2011 Sept 09); available from //clinicaltrials.gov/ct2/show/ NCT01004224, identifier NCT01004224.
47. Morozova O, Marra MA: Applications of nextgeneration sequencing technologies in functional genomics. Genomics 2008;92:255-64.
48. Natrajan R, Reis-Filho JS: Next-generation sequencing applied to molecular diagnostics. Expert Rev Mol Diagn 2011;11:425-44.
49. Bell DW: Our changing view of the genomic landscape of cancer. J Pathol 2010;220:231-43.